Gene therapy for
advanced coronary artery disease

XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.

Latest News

Press Release: May 18, 2022
XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT
More >>

See Our Pipeline

XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
More >>

Research & Development

XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.
More >>